Press Release Hub logo
  • Submit a Release
  • Home
  • All
  • ESG
  • Health
  • Technology
  • Finance
  • Contributors

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform

Contributed by: Business Wire

Logo

Business Wire logo

Tags

Oncology
Nursing
Health
Infectious Diseases
Clinical Trials
Pharmaceutical
Biotechnology
Centivax

More Like This

Business Wire logo

Meiji Seika Pharma Opens New Office in Boston Area to Pursue Investment Opportunities in Innovative Drugs and Technologies

Business Wire logo

Meiji Seika Pharma Invests in Lyric Bio for Next-Generation Human Immunoglobulin Manufacturing

PR Newswire associated0

Centivax Selects Global CDMO BioCina to Initiate cGMP Manufacturing of Revolutionary Universal Influenza Vaccine

Business Wire logo

Meiji Seika Pharma Partners With MBC BioLabs to Strengthen Global Innovation in Drug Discovery

Business Wire logo

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund

Business Wire logo

Meiji Seika Pharma Invests in MPM BioImpact’s New Technologies and Virology Strategy

Business Wire logo

Meiji Group to Showcase Japanese-Quality CMO/CDMO Services and a Global Manufacturing Network at CPHI Milan 2026

UK Government Strengthens Vaccine Partnership with CSL Seqirus, Introducing World-First Flu vaccine (aTIVc) and Extending Health Security Pandemic Agreement

Pages

  • Home
  • All
  • ESG
  • Health
  • Technology
  • Finance
  • Contributors

Press Release Hub

  • Our Services
  • Submit a Release

Websites

  • PA Media Group
  • PA Mediapoint
  • Distribution Packages

© PA Media Group. 2026

Terms of Use

Privacy Policy

Contact Us